ENLIVEN THERAPEUTICS, INC. (ELVN) Free cash flow 2019–2025
ENLIVEN THERAPEUTICS, INC. (ELVN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$70.5MFY2025 · since FY2019: -$22.0M → -$70.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$70.5M | +3.8% |
| FY2024 | -$73.2M | -19.2% |
| FY2023 | -$61.4M | -87.9% |
| FY2022 | -$32.7M | +30.1% |
| FY2021 | -$46.8M | -25.0% |
| FY2020 | -$37.4M | -69.9% |
| FY2019 | -$22.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELVN financial trends
ELVN RevenueELVN Net incomeELVN Net marginELVN Gross profitELVN Gross marginELVN Operating incomeELVN Operating marginELVN Operating cash flowELVN Capital expendituresELVN Return on equityELVN Stock buybacksELVN Dividends paidELVN Total assetsELVN Total liabilitiesELVN Shareholders’ equityELVN overview →